Alzamend Neuro, Inc. (ALZN), Thursday announced positive topline data from its first Phase II 'Lithium in Brain' clinical trial.
The trial showed that AL001 meets bioequivalence standards while also showing numerically superior lithium delivery to the brain compared to standard lithium carbonate across all 26 measured brain regions including whole brain.
Additionally, AL001 delivered 101 percent of total lithium blood exposure and 97 percent of peak lithium levels vs. standard lithium carbonate. It reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonate.
The company is expected to commence the third, fourth, and fifth studies in the program enrolling patients with MDD, PTSD and Alzheimer's, respectively, in the latter half of 2026, subject to raising sufficient capital.
Currently, ALZN is trading at $1.5, down 22.28 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.